{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"82.8"},{"groupId":"OG001","value":"29.4"},{"groupId":"OG002","value":"94.0"},{"groupId":"OG003","value":"96.1"},{"groupId":"OG004","value":"90.9"}]}],"title":"Complete (0%)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.9"},{"groupId":"OG001","value":"23.5"},{"groupId":"OG002","value":"2.4"},{"groupId":"OG003","value":"2.0"},{"groupId":"OG004","value":"3.0"}]}],"title":"Partial (>0% - 35%)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.4"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}]}],"title":"Minor (>35% - 65%)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.4"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1.2"},{"groupId":"OG003","value":"2.0"},{"groupId":"OG004","value":"0"}]}],"title":"Minimal (>65% - 95%)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"5.9"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}]}],"title":"No Response (>95% - 100%)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.4"},{"groupId":"OG001","value":"41.2"},{"groupId":"OG002","value":"2.4"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"6.1"}]}],"title":"Unable to Determine"}],"denoms":[{"counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"84"},{"groupId":"OG003","value":"51"},{"groupId":"OG004","value":"33"}],"units":"Participants"}],"description":"The number of participants achieving their best on-study cytogenetic response was reported as a percentage of all treated participants in that arm. (Based on \\>=20 Metaphases)","groups":[{"description":"Children and adolescents with CP-CML who were resistant or intolerant to imatinib received dasatinib tablets at 60 mg/m2 QD on a continuous oral regimen.","id":"OG000","title":"Cohort 1"},{"description":"Children and adolescents with Ph+ ALL, AP-CML or BP-CML who were resistant or intolerant to, or relapsed after imatinib therapy received dasatinib tablets at a dose schedule of 80 mg/m2 QD on a continuous oral regimen.","id":"OG001","title":"Cohort 2"},{"description":"Children and adolescents with CP-CML who were treatment-naive received dasatinib tablets at 60 mg/m2 QD or powder for oral suspension (PFOS) at 72 mg/m2 QD on a continuous oral regimen.","id":"OG002","title":"Cohort 3"},{"description":"Children and adolescents with CP-CML who were treatment-naive received dasatinib tablets at 60 mg/m2 QD on a continuous oral regimen.","id":"OG003","title":"Cohort 3a"},{"description":"Children and adolescents with CP-CML who were treatment-naive received dasatinib powder for oral suspension (PFOS) at 72 mg/m2 QD on a continuous oral regimen.","id":"OG004","title":"Cohort 3b"}],"paramType":"NUMBER","populationDescription":"All treated participants","reportingStatus":"POSTED","timeFrame":"From first dose of study therapy until 30 days after last dose (Assessed up to September 2016, approximately 90 months)","title":"Rate of Best Cytogenetic Response","type":"SECONDARY","unitOfMeasure":"percentage of participants"}